Zhou M X, Findley H W, Ma L H, Zaki S R, Hill T, Hamid M, Hooper W C, Ragab A H
Division of Pediatric Hematology/Oncology, Emory University, Atlanta, GA 30322.
Blood. 1991 May 1;77(9):2002-7.
The effect of recombinant tumor necrosis factor-alpha (rTNF-alpha) on the primary leukemic blasts and leukemic cell lines derived from children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) was studied. The proliferation of leukemic cells from the bone marrow of 11 of 13 patients (seven at diagnosis, four in relapse) and from the 697 (BCP-ALL) cell line was significantly inhibited by rTNF-alpha at the lowest dose tested (0.1 ng/mL), as measured by 3H-TdR uptake. The degree of inhibition was variable, ranging from 17% to 78%. Furthermore, a dose-dependent inhibitory effect was observed, with approximately 70% mean inhibition of DNA synthesis detected when cells from 12 of 13 patients were incubated with 100 ng/mL of rTNF-alpha for 3 days. In contrast, rTNF-alpha did not inhibit another BCP-ALL cell line (EU-1/ALL) established recently in our laboratory. Studies indicated that the TNF-alpha gene was expressed by the primary leukemic blasts of one TNF-resistant case in his third relapse and by EU-1 cells. Also, TNF-alpha protein was detected by Western blot analysis and enzyme-linked immunoabsorbent assay in the supernatant of EU-1 cells; this is the first report of TNF production by a BCP-ALL cell lines. The production of TNF-alpha mRNA and protein was not detected in the 697 cell line and in the primary leukemic blasts from six patients (four at diagnosis, two in relapse) whose leukemic cells were inhibited by TNF. The partially purified TNF-alpha obtained from the EU-1 cell line also suppressed the proliferation of TNF-sensitive primary leukemic cells, and this inhibitory activity was abolished by an anti-TNF-alpha specific antibody. Our results demonstrate that TNF-alpha is an inhibitor of in vitro proliferation of BCP-ALL cells from most patients. The TNF-resistant leukemic cells from a few patients and the EU-1 cell line express TNF mRNA, suggesting that the induction of TNF gene expression is associated with the development of TNF resistance.
研究了重组肿瘤坏死因子-α(rTNF-α)对源自B细胞前体急性淋巴细胞白血病(BCP-ALL)患儿的原发性白血病原始细胞和白血病细胞系的影响。通过3H-TdR摄取测定,rTNF-α在测试的最低剂量(0.1 ng/mL)时,显著抑制了13例患者中11例(7例诊断时,4例复发时)骨髓白血病细胞以及697(BCP-ALL)细胞系的增殖。抑制程度各不相同,范围从17%至78%。此外,观察到剂量依赖性抑制作用,当13例患者中的12例细胞与100 ng/mL的rTNF-α孵育3天时,平均约70%的DNA合成受到抑制。相比之下,rTNF-α未抑制我们实验室最近建立的另一个BCP-ALL细胞系(EU-1/ALL)。研究表明,TNF-α基因在1例TNF耐药病例第三次复发时的原发性白血病原始细胞以及EU-1细胞中表达。此外,通过蛋白质印迹分析和酶联免疫吸附测定在EU-1细胞的上清液中检测到TNF-α蛋白;这是关于BCP-ALL细胞系产生TNF的首次报道。在697细胞系以及白血病细胞被TNF抑制的6例患者(4例诊断时,2例复发时)的原发性白血病原始细胞中未检测到TNF-α mRNA和蛋白的产生。从EU-1细胞系获得的部分纯化TNF-α也抑制了TNF敏感的原发性白血病细胞的增殖,并且这种抑制活性被抗TNF-α特异性抗体消除。我们的结果表明,TNF-α是大多数患者BCP-ALL细胞体外增殖的抑制剂。少数患者的TNF耐药白血病细胞和EU-1细胞系表达TNF mRNA,提示TNF基因表达的诱导与TNF耐药的发生有关。